Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3887396rdf:typepubmed:Citationlld:pubmed
pubmed-article:3887396lifeskim:mentionsumls-concept:C0004482lld:lifeskim
pubmed-article:3887396lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:3887396lifeskim:mentionsumls-concept:C0032950lld:lifeskim
pubmed-article:3887396lifeskim:mentionsumls-concept:C0439836lld:lifeskim
pubmed-article:3887396pubmed:dateCreated1985-6-19lld:pubmed
pubmed-article:3887396pubmed:abstractTextOut of 58 consecutive cadaveric renal allograft recipients whose initial immunosuppression was cyclosporine (Cys) and prednisolone, 18 were converted to prednisolone and azathioprine. Of these all four patients converted because of rejection lost their grafts. Renal function improved in seven patients converted because of nephrotoxicity and in six out of seven patients converted for miscellaneous reasons. Out of five patients converted electively at three months, one died of infection and three developed acute rejection episodes.lld:pubmed
pubmed-article:3887396pubmed:languageenglld:pubmed
pubmed-article:3887396pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3887396pubmed:citationSubsetIMlld:pubmed
pubmed-article:3887396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3887396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3887396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3887396pubmed:statusMEDLINElld:pubmed
pubmed-article:3887396pubmed:issn0308-9401lld:pubmed
pubmed-article:3887396pubmed:authorpubmed-author:McMasterPPlld:pubmed
pubmed-article:3887396pubmed:authorpubmed-author:MichaelJJlld:pubmed
pubmed-article:3887396pubmed:authorpubmed-author:AduDDlld:pubmed
pubmed-article:3887396pubmed:authorpubmed-author:VlassisTTlld:pubmed
pubmed-article:3887396pubmed:issnTypePrintlld:pubmed
pubmed-article:3887396pubmed:volume21lld:pubmed
pubmed-article:3887396pubmed:ownerNLMlld:pubmed
pubmed-article:3887396pubmed:authorsCompleteYlld:pubmed
pubmed-article:3887396pubmed:pagination998-1001lld:pubmed
pubmed-article:3887396pubmed:dateRevised2008-2-26lld:pubmed
pubmed-article:3887396pubmed:meshHeadingpubmed-meshheading:3887396-...lld:pubmed
pubmed-article:3887396pubmed:meshHeadingpubmed-meshheading:3887396-...lld:pubmed
pubmed-article:3887396pubmed:meshHeadingpubmed-meshheading:3887396-...lld:pubmed
pubmed-article:3887396pubmed:meshHeadingpubmed-meshheading:3887396-...lld:pubmed
pubmed-article:3887396pubmed:meshHeadingpubmed-meshheading:3887396-...lld:pubmed
pubmed-article:3887396pubmed:meshHeadingpubmed-meshheading:3887396-...lld:pubmed
pubmed-article:3887396pubmed:meshHeadingpubmed-meshheading:3887396-...lld:pubmed
pubmed-article:3887396pubmed:year1985lld:pubmed
pubmed-article:3887396pubmed:articleTitleConversion from cyclosporine to prednisolone and azathioprine. Safe or unsafe?lld:pubmed
pubmed-article:3887396pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3887396pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3887396pubmed:publicationTypeComparative Studylld:pubmed